Cullen Investment Group LTD. Purchases 614 Shares of DexCom, Inc. (NASDAQ:DXCM)

Cullen Investment Group LTD. boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,502 shares of the medical device company’s stock after acquiring an additional 614 shares during the quarter. Cullen Investment Group LTD.’s holdings in DexCom were worth $895,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in DXCM. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter valued at about $25,000. Riverview Trust Co raised its holdings in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the third quarter valued at about $57,000. Covestor Ltd raised its stake in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in DexCom by 101.9% in the 3rd quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after purchasing an additional 898 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $79.84 on Tuesday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company’s fifty day moving average price is $77.13 and its two-hundred day moving average price is $78.59. The firm has a market capitalization of $31.19 billion, a P/E ratio of 47.81, a P/E/G ratio of 2.36 and a beta of 1.12.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on DXCM. Canaccord Genuity Group lifted their target price on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Citigroup increased their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada reduced their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Sanford C. Bernstein boosted their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, Leerink Partners reduced their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $98.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.